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The tandem GAF domains from the cyanobacterium Anabaena
PCC7120 cyaB2 adenylyl cyclase form an antiparallel dimer with
cAMP bound to all four binding sites. cAMP binding causes highly
cooperative allosteric enzyme activation (>500-fold; EC50  1 M;
Hill coefficient >2.0). The cyaB2 GAF domains, like those of the
cyclic nucleotide phosphodiesterases (PDEs), contain conserved
NKFDE motifs that when mutated in the PDEs abrogate cyclic
nucleotide binding. We mutated the aspartic acids within this motif
in cyaB2 to determine which domains were required for signaling.
Constructs containing an AspAla mutation in either GAF domain
still showed positive cooperative cAMP stimulation but with re-
duced Hill coefficients. The cyaB2 GAF domain NKFDE motifs
contain inserts of 14 (GAF-A) and 19 (GAF-B) amino acids not
present in PDE2 or cyaB1. Constructs having these inserts deleted
could still be activated by cAMP (23- to 100-fold) but lost all positive
cooperative activation, suggesting that the inserts play an impor-
tant role in domain interaction andor stabilization of the cAMP-
binding pockets. In the shortened constructs, even those with a
single AspAla mutation in the NKFDE motifs could still be acti-
vated by cAMP. However, in a double AspAla mutant of the
shortened construct, stimulation by cAMP was almost completely
lost, and the EC50 shifted far to the right. Overall, the data suggest
that in GAF domains without these inserts, only the canonical
lysine:aspartate salt bridge keeps the 4-helix and the 4-5 linker
that close over the cyclic nucleotide properly oriented, thereby
stabilizing the binding pocket. The cyaB2 GAF ensemble appears to
be an evolutionary intermediate where both GAF domains still
participate in allosteric activation by cAMP.
PDE  phosphodiesterase
GAF domains are widespread small-molecule-binding do-mains that are present in1,600 proteins from all kingdoms
of life (1–4). The acronym is derived from those proteins in
which these domains were initially identified, i.e., in cGMP-
regulated mammalian phosphodiesterases (PDEs), cyanobacte-
rial adenylyl cyclases (ACs), and a formate-hydrogen lyase
transcriptional activator. In the mammalian PDEs 2, 5, 6, 10, and
11 and in the cyanobacterial ACs cyaB1 and cyaB2, two GAF
domains are located N-terminally in tandem (4). Cyclic nucle-
otides serve as allosteric regulators that activate these C-
terminally located effector domains (2, 4–9).
In 2002, the structure of a PDE2 tandem GAF domain was
solved at 2.9 Å (10). It showed a parallel dimer in which the
N-terminal GAF-A domains were physically dimerized, whereas
the GAF-B domains each contained a molecule of bound cGMP
and were 65 Å apart. Mutagenesis experiments confirmed that
GAF-B is the cyclic-nucleotide-binding domain in PDE2 (11).
Most surprisingly, the tandem GAF domains of this mammalian
PDE2 could functionally replace those of the cyanobacterial AC,
cyaB1 (9). That is, a cAMP-regulated cyanobacterial AC was
converted into a cGMP-regulated enzyme. The elucidation of
the structure of the tandem GAF domains from the closely
related cyanobacterial AC, cyaB2, at a 1.9-Å resolution provided
another surprise (12). These GAF domains formed a more
closely packed antiparallel dimer that has a molecule of cAMP
bound to all four individual GAF domains. In both structures,
however, the regions around each of the cyclic-nucleotide-
binding sites was rather well conserved and in all instances the
bound cyclic nucleotides were almost totally buried inside the
proteins. Here, we present a structure-guided biochemical anal-
ysis of cAMP signaling by the cyaB2 tandem GAF domain based
on a functional activation assay. For technical reasons a chimera
of cyaB2 GAF domains fused with the cyaB1 catalytic domain
was used as an analytical tool (9) because the cyaB2 holoenzyme
which also is cAMP stimulated, was difficult to express, unstable
and could not be purified. Because in the crystal structure all
four potential ligand-binding domains contained cAMP, we
wanted to determine whether all of these binding sites actually
contribute to intramolecular signaling.
As part of this investigation we characterized the role of a
lysine:aspartate salt-bridge found in the conserved NKFDE
motif [a conserved signature motif of the amino acids Asn(N),
Lys(K), Phe(F), Asp(D), and Glu(E) found in all GAF-domain-
containing enzymes that have cyclic-nucleotide-binding capac-
ity] that has been identified in the GAF domains of five
mammalian PDEs and the two cyanobacterial ACs, cyaB1 and
cyaB2 (4, 13). Both available GAF domain structures, the
parallel one from PDE2 and the antiparallel one from cyaB2,
established that the signature NKFDE motif that contains a
conserved lysine:aspartate salt bridge is adjacent to the binding
sites and not directly involved in ligand binding. In the PDEs and
cyaB1, mutation of the conserved aspartates within this motif to
alanine reduced or eliminated ligand binding or activation and
thus has been used to identify which of the potential cyclic-
nucleotide-binding sites actually mediates intramolecular signal-
ing (2, 6, 9, 14, 15). The cyaB2 tandem GAF domains contain as
unique structural features either 14- or 19-aa inserts between the
conserved Lys and Phe of the NKFDE motif in GAF-A and -B,
respectively (Fig. 1) (12). By deletion mutagenesis, we now
establish that these inserts are essential for positive cooperative
cAMP signaling. In addition, they complement the function of
the stabilization function of the lysine:aspartate salt bridge.
Finally, the biochemical experiments provide evidence that in
cyaB2, both the GAF-A and the GAF-B ligand-binding regions
participate in AC activation as suggested by the crystal structure
and the large Hill coefficient.
Materials and Methods
CyaB2-GAF-cyaB1-Chimera. The cyaB2 gene from Anabaena
PCC7120 was a gift of M. Ohmori (University of Tokyo). The
cyaB2 tandem GAF-domain (amino acids 1–441) was amplified
by PCR with specific primers. It was cloned into pBluescriptII
Abbreviations: AC, adenylyl cyclase; PDE, phosphodiesterase; shGAF, shortened GAF.
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SK() via BamHI and XhoI sites and placed upstream of the
cyaB1 AC beginning at amino acid 386. By transfer to pQE30 the
construct was fitted with an N-terminal MRGSH6GS affinity
tag.
CyaB2-GAF-Asp224Ala, -Asp416Ala, and -Asp224AlaAsp416Ala-
Adenylyl Cyclase Mutations. Single amino acid mutations
(Asp224Ala, Asp416Ala) were introduced by site-directed
mutagenesis with respective PCR primers and the cyaB2-GAF-
cyaB1-chimera in pBluescriptII SK() as a template. Restric-
tion sites located nearby were used. These constructs were
transferred into the expression vector pET16b via NdeI and
BamHI sites attaching an N-terminal MGH10SSGHIEGR
affinity tag.
CyaB2-shGAF, shGAF-Asp224Ala, -Asp416Ala, and -Asp224Ala
Asp416Ala-Adenylyl Cyclases. A shortened version of cyaB2 GAF
[cyaB2-shGAF (202–215Lys388Gly389–407)-cyaB1-
chimera; see alignment in Fig. 1 for further details] was gener-
ated by site-directed mutagenesis with deletion primers and the
cyaB2-GAF-cyaB1-chimera in pBluescriptII SK() as a tem-
plate. The constructs were cloned into the BamHI and SmaI sites
of pQE30 attaching an N-terminal MRGSH6GS affinity tag. The
fidelity of all constructs was verified by double-stranded se-
quencing. Primer sequences are available on request.
Expression and Purification of Bacterially Expressed Proteins. All
pQE30 constructs were transformed into Escherichia coli
BL21(DE3)[pRep4] and pET16b clones into E. coli
BL21(DE3)[pLysS]. Cultures were grown in Lennox L broth at
30°C containing 100 mgliter ampicillin and 25 mgliter kana-
mycin. Expression was induced at an A600 of 0.6 with 25–40 M
isopropyl--thiogalactopyranoside for 4 to 5 h at 16–19°C.
Bacteria were harvested and washed once with 50 mM TrisHCl
(pH 8.5) at 4°C and stored at 80°C. For purification, frozen
cells were suspended in 25 ml of cell lysis buffer (50 mM
TrisHCl, pH 8.550 mM NaCl7.5 mM imidazoleprotease
inhibitors20% glycerol) at 4°C and passed through a French
press at 1,000 psi (1 psi  6.89 kPa). Cell debris was removed by
centrifugation (48,000  g for 45 min). Fifty to 200 l of
Ni2-NTA slurry (Qiagen) was added to the supernatants. After
binding for several hours at 0°C, the resin was poured into a
column and washed (2 ml per wash). Wash buffer A was 50 mM
TrisHCl (pH 8.5)2 mM MgCl2400 mM NaCl5 mM imida-
zole20% glycerol; wash buffer B contained 15 mM imidazole.
Wash buffer C was as A with 10 mMNaCl and 25 mM imidazole.
Proteins were eluted with 0.2–0.4 ml of buffer C containing 300
mM imidazole. Full AC activity is detectable in the eluate;
however, imidazole impaired stability, and samples were dia-
lyzed for 2 h against 50 mM TrisHCl (pH 8.5)10 mM NaCl2
mM MgCl235% glycerol (9). Protein was stored at 20°C.
Adenylyl Cyclase Assay.AC activity routinely was measured in 100
l at 37°C for 4 or 10 min (16). The reactions contained 22%
glycerol, 50 mM TrisHCl (pH 7.5), 10 mM MgCl2, and 75 M
[-32P]ATP (25 kBq). [2,8-3H]cAMP (150 Bq) was added after
stopping the reaction to determine yield during product isola-
tion. The protein concentration was adjusted to keep substrate
conversion below 10%. The reaction was started by addition of
the substrate.
Western Blot Analysis. Protein was mixed with sample buffer and
subjected to SDSPAGE (10%). Proteins were blotted on PVDF
membranes and sequentially probed with a commercial anti-
RGS-H4-antibody (Qiagen) and with a 1:5,000 dilution of a
peroxidase-conjugated goat anti-mouse IgG secondary antibody
(Dianova, Hamburg, Germany). Peroxidase detection was car-
ried out with the ECL Plus kit (Amersham Pharmacia).
Results and Discussion
In a construct consisting of the cyaB2 tandem GAF domain and
the cyaB1 AC catalytic domain, cAMP stimulated enzyme
activity 500-fold in a dose-dependent manner and with very
high specificity. The EC50 concentration for half-maximal acti-
vation was 1.3 M cAMP (Fig. 2A and Table 1), i.e., almost
identical to that for cyaB1 (9). cGMP had almost no effect up to
100 M. Remarkably, the cAMP dose–response curve showed
that full activation was accomplished over only a 10-fold con-
centration range from 0.3 to 3 M. Accordingly, a Hill coeffi-
cient of 2.2 indicated strong positive cooperativity (Table 1).
This differed from cyaB1 GAF-domain-mediated activation that
had a Hill coefficient of 0.7, i.e., it had no positive cooperativity.
AC activation via cyaB2 GAF domains was not affected by
Fig. 1. CyaB2 GAF domains have an insert in the conserved NKFDE motif. (A)
Alignment of NKFDE motifs of GAF-B from rat PDE2, GAF-A from human PDE5,
GAF-B from the Anabaena sp. PCC7120 cyaB1 AC, and GAF-A and -B from
cyaB2 AC. The invariant residues of the NKFDE motif are marked on top and
beneath by black dots. Note the inserts in the cyaB2 GAF-A and -B regions. The
vertical lines denote the section that was removed in the shortened cyaB2
tandem GAF domain (shGAF). The final sequence between the conserved Lys
and Phe in cyaB2 shGAF-A was LDNQG and in GAF-B was GFQAS. (B and C) A
close-up of structural details shows the extended sequence element in cyaB2
GAF-A (B) and -B (C). The insert loops are yellow, the five NKFDE side chains are
orange, cAMP is red, and the Thr-176 (GAF-A) or Thr-363 (GAF-B) is magenta.
Some of the residues that interact between the inserts and the remainder of
the GAF domain are shown (green). Hydrogen bonds are dashed yellow lines.
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preincubation with cAMP on ice for up to 45 min before
substrate addition. Similarly, the activation was reversible in-
stantaneously, i.e., the on- and off-rates and presumably the
allosteric changes in response to binding were very rapid.
The cyaB2 tandem GAF domain is similar to its cyaB1
congener and also to the tandem GAF domains from mamma-
lian phosphodiesterases PDE2 (24% identity and 43% similarity)
and PDE5 (22% identity and 43% similarity), which are stimu-
lated by cGMP via their respective GAF-B and GAF-A domains
(8, 10, 11, 17). All of these tandem GAF domains share a
conserved NKFDE motif that is present in both GAF-A and -B
(Fig. 1A). Because these motifs are not close to the binding
pockets they clearly are not directly involved in cyclic nucleotide
binding or discrimination (10, 12). However, they must indirectly
affect signaling from the binding site because several studies
have successfully used mutations of the invariant aspartate in the
NKFDE motif (2, 6, 9, 14) to determine which of the GAF
domains, GAF-A or -B, mediate binding of cyclic nucleotide or
activation of the associated target enzyme. Such studies have
shown that GAF-B in PDE2, GAF-A in PDE5, and GAF-B in
cyaB1 are the cyclic-nucleotide-binding domains (9–11, 17).
Surprisingly, in the crystal structure of cyaB2, both domains,
GAF-A and GAF-B, were found to contain bound cAMP.
Therefore, the question arose whether both cAMP-binding sites
also contribute to activation.
A comparison of the structures of the cyaB2 and PDE2 GAF
domains (10, 12) showed that the salt bridges between the
invariant Lys and Asp of the NKFDE motif in GAF-A and -B
were retained in all four cyaB2-GAF domains of the dimer (Fig.
1 B and C). The distances were 2.6 Å from Lys-200 to Asp-224
in GAF-A and 3.3 Å from Lys-387 to Asp-416 in GAF-B. A
superimposition of the NKFDE motif between the structures of
PDE2 GAF-B and both GAF domains of cyaB2 matched
excellently with rms deviation values of 0.91 Å (GAF-A of cyaB2
to GAF-B of cyaB2), 0.98 Å (GAF-A of cyaB2 to GAF-A of
PDE2), and 2.06 Å (GAF-A of cyaB2 to GAF-B of PDE2). The
14- and 19-aa inserts, compared with PDE2, between Lys and
Asp in cyaB2 form distinct additional elements that do not, by
themselves, affect the positions of the NKFDE amino acids (Fig.
1) (12). However, from the cyaB2 GAF tandem structure, a
distinct function for these inserts could not be deduced (12).
In contrast to cyaB1, the cyaB2cyaB1 chimeric AC showed
highly positive cooperative activation by cAMP (Hill coefficient
of 2.2; Table 1). These data suggested that both GAF domains
might be required for full activation. To examine biochemically
whether both cyaB2 GAF domains mediate cAMP activation, we
mutated Asp-224 in GAF-A and Asp-416 in GAF-B to Ala
according to established strategies (6). As mentioned above, in
all other GAF domains this mutation greatly weakened or
completely abolished binding or activation. Therefore, it was a
somewhat of a surprise that both individual AspAla mutants
were fully functional (Fig. 2B). The dose–response curves for
cAMP-stimulated cyclase activity were, however, less steep for
the individual cyaB2D224A and cyaB2D416A mutant proteins
(400- to 800-fold stimulation). This difference was reflected in a
drop of the Hill coefficients from 2.2 to 1.4 and 1.6, respectively.
The EC50 concentrations for cAMP of 0.5 M and 0.3 M for
Fig. 2. Stimulation of the cyaB1 ACs via the cyaB2 tandem GAF domain wild
type and mutants. (A) Wild-type tandem GAF domain (squares, cAMP; circles,
cGMP). (B) Stimulation by cAMP of the point mutant proteins cyaB2 tandem
GAF Asp224Ala (squares, mutation of conserved Asp in GAF-A) and tandem
GAF D416A (circles, mutation of conserved Asp in GAF-B). For clarity, corre-
sponding dose–response curves for cGMP are not depicted. The EC50 concen-
trations for cGMP were 40M for the Asp224Ala and 63M for the Asp416Ala
mutant, respectively. (C) cyaB2 tandem GAF domain double mutant
Asp224AlaAsp416Ala (squares, cAMP; circles, cGMP). Western blots of the
respective proteins are shown on the right side of each figure.
Table 1. EC50 values and Hill coefficients for all constructs
examined in this study
Construct EC50 cAMP, M
Fold
stimulation
Hill
coefficient
Wild type 1.3 500–1,000 2.2
D224A 0.5 430 1.4
D416A 0.3 850 1.6
D224AD416A 0.3 625 1.7
shGAF 1 100 0.7
shGAF D224A 1.6 23 0.5
shGAF D416A 65 76 0.6
shGAF D224AD416A 450 6 0.7
Data are means of two to four separate experiments for each condition. Hill
coefficients are based on linear regression analysis of data plotted in EXCEL
(Microsoft). The correlation coefficient for all constructs was 0.9 or higher.
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GAF-A Asp224Ala and GAF-B Asp416Ala were similar to the
unmutated cyaB2 GAF domains (Fig. 2B). More surprisingly, in
the double mutant, Asp224AlaAsp416Ala, the potency of
cAMP to activate the cyclase was fully sustained (600-fold
activation) and the EC50 of 0.3 M cAMP was again identical to
the unmutated domains (Fig. 2C). The Hill coefficient of 1.7 was
reduced from that of the unmutated construct. The specificity
for cAMP compared to cGMP was retained for all these mutants
(Fig. 2).
The surprising lack of an effect of the AspAla mutations at
these positions that was in stark contrast to observations with
respective mutations in PDE2, PDE5, and cyaB1 (2, 6, 9, 11, 14)
demonstrated that the invariant aspartates are not required for
coupling of intramolecular signaling in this cyclase. However, the
decrease in positive cooperativity further suggested that both
cAMP-binding domains were required for full cooperative
activation.
It has been postulated that the conserved lysine:aspartate salt
bridge may stabilize the cyclic-nucleotide-binding pocket as
mutations of these residues greatly reduced or abolished cGMP
binding in PDEs 2, 5, and 6 (2, 6, 11, 14). Similarly, mutations
of the conserved Asn of the NKFDE motif also reduced or
abolished cGMP binding (11, 15). Examination of the structure
of either of the cyaB2 GAF domains showed that Asn-386 in
GAF-B or Asn-199 in GAF-A (i.e., the conserved Asn in each
NKFDE motif) makes multiple hydrogen bonds to backbone
amides and a carbonyl in the 4-5 linker (Fig. 1 B and C),
thereby presumably stabilizing the pocket. The neighboring
lysine:aspartate salt bridge therefore provides a strong interac-
tion with the 5-helix, thereby stabilizing the orientation of these
two structural elements. However, the data from the mutations
in the cyaB2 GAF domains described above were not consistent
with the data from the same mutations described for the PDEs
because both AspAla mutants in the cyaB2-GAF-cyaB1 AC
construct had essentially undiminished signaling capacity. The
activation factor for cAMP was 400-fold for all full-length
cyaB2 GAF constructs (Table 1). Therefore, we suspected that
the inserts of 14 and 19 aa between the conserved Lys and Phe
of the NKFDE motif in the cyaB2 GAF-A and GAF-B domains,
respectively, might be responsible for these unexpected results.
These additional amino acids are located close to the 4 helical
rim of the cAMP-binding pocket, particularly in GAF-B. As
shown in Fig. 1B, there also are multiple contacts between
several of these amino acids and the 4-5 linker that connects
the 4-helix with the -sheet or a more rigid structural unit
composed of the -sheet and helices 2 and 5. Therefore,
the possibility existed that these extra loops stabilized the
position and orientation of the 4-helix and the important
Thr-176 and Thr-363 side chains in the cAMP-binding pockets
such as to make the otherwise necessary lysine:aspartate salt
bridges dispensable.
Therefore, we deleted the intervening sequences from Lys-202
to Ile-215 in GAF-A and from Lys-389 to Cys-407 (Lys-388 was
replaced by a Gly; see Fig. 1A) in GAF-B to bring the cyaB2
tandem GAF domain to length-conformity with the PDE2
congener. This construct was termed cyaB2-shGAF and used to
test the question of whether the shortened AC constructs could
be activated by cAMP. Because formation of the lysine:aspartate
salt bridge still should be possible, it was predicted that the
dose–response curves for cAMP and cGMP ought to be identical
to the unabridged version. In fact, the EC50 value for activation
was similar (1 M cAMP); however, maximal stimulation was
only 100-fold, and cGMP was essentially inactive as an activator
(Fig. 3A and Table 1). Notably, the Hill coefficient dropped to
0.7 (Table 1). This result was more akin to previous data seen
with the cyaB1 tandem GAF domains that also showed a Hill
coefficient of 0.7 and the PDE2-GAF chimera with the cyaB1
AC with a Hill coefficient of 0.9. Therefore, the additional 14
and 19 aa appeared not to be required for activation, yet their
presence was required for the positive cooperativity of cAMP as
an activator (Table 1). Next, we generated single AspAla
mutations at either Asp-224 in shGAF-A or Asp-416 in
shGAF-B (Fig. 3B). Somewhat surprisingly, each individual
mutant AC construct was subject to cAMP stimulation albeit to
different extents (Fig. 3B). In the cyaB2-shGAFA-Asp224Ala
mutant, the stimulation was 20-fold, and the EC50 for cAMP
was 1.6 M, i.e., only somewhat less efficacious than for the
unmutated protein (Table 1). In the cyaB2-shGAFB-D416A
mutant, the stimulation was 70-fold, but the EC50 was 65 M
cAMP, i.e., 30-fold higher than in the cyaB2-shGAFA-
Asp224Ala construct. The Hill coefficients were 0.5 and 0.6,
respectively, i.e., the loss of cooperativity was also apparent in
these mutations and corresponded to that observed in the
shGAF-cyclase construct. Nevertheless, in both mutant proteins
a functional coupling between the tandem GAF domain and the
catalytic region was retained. Taken together, the data strongly
imply that both cAMP-binding GAF domains participate in
cooperative activation as predicted by the Hill coefficient of the
unmutated construct and the fact that all four GAF domains in
the crystal structure contained bound cAMP. The data also
support the idea that the conserved aspartate residues of the
NKFDE motif are not required for signal coupling between the
regulatory and catalytic domains in this cyclase. Furthermore, it
is likely that the Hill coefficients 1 are due to differences in
cAMP affinities of the GAF-A and GAF-B domains (Fig. 3B).
Such differences would result in an apparent Hill coefficient of
1 unless a strong positive cooperativity still existed. Therefore,
Fig. 3. Stimulation of cAMP formation via a cyaB2 tandem GAF domain with
shortened NKFDE region (shGAF). (A) Stimulation by cAMP (squares) and
cGMP (circles) via cyaB2 shGAF. (B) Stimulation in shGAF-Asp224Ala (circles)
and shGAF-Asp416Ala (squares). The Inset shows the cAMP stimulation of the
shGAF-Asp224AlaAsp416Ala quadruple mutant (same scale as main figure).
The corresponding Western blots are to the right.
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the data suggest that little or no positive cooperativity exists
between GAF-A and GAF-B in these mutants.
Next, we mutated the aspartate residues in both GAF domains
by introducing one or more mutations into shGAF-A D224A
(wild-type numbering), thereby generating a cyaB2 shGAF-
Asp224AlaAsp416Ala-cyaB1 cyclase mutant. The basal activity
of this shortened double mutant was 0.4 	 0.1 nmol of
cAMPmg1min1 (SD; n  6), which is at the lower end of the
basal activities of the other mutant proteins. Cyclase activity was
linear with respect to protein concentration and time. Further-
more, enzyme activity of this mutant was inhibited 75% by 1
mM ,-imido-GTP (GMPPNP), as were the activities of the
wild-type construct, the individual shGAF single AspAla mu-
tants, and the cyanobacterial cyaB1 AC (data not shown). These
findings suggest that the basic enzymatic properties of the
catalytic domain were functionally identical to those of the other
mutant cyclases. Finally, a dose–response curve with cAMP
showed that this quadruple mutant could be stimulated 6-fold
but only by very high concentrations of cAMP (Fig. 3B Inset).
The EC50 was 450 M cAMP and the Hill coefficient for
activation was 0.7, in line with a general loss of positive coop-
erativity in all of the shGAF constructs (Table 1). The residual
activation showed that signal coupling in the protein was func-
tional in principle. Evidently, this protein could not be fully
stimulated anymore because both cAMP-binding domains were
only marginally effective. This interpretation is consistent with
all earlier reports relating to mutations of the conserved Asp of
the NKFDEmotif and, most importantly, agrees with the finding
that in the crystal structure, all four potential cAMP-binding
sites are occupied by cAMP compared with only two cGMP
molecules being bound in the PDE2 GAF structure.
Taken together, the data strongly suggest that the inserts in
cyaB2 have a dual function. First, they stabilize the cAMP-
binding site and make the lysine:aspartate salt bridge dispens-
able. Secondly, they enable positive cooperativity of cAMP-
mediated activation between GAF-A and GAF-B in that when
both are activated in concert, this leads to extraordinary high
levels of stimulation. Moreover, this cooperativity is enabled or
enhanced by salt bridges that are likely to exist between the
respective GAF-A and GAF-B domains of each monomer, e.g.,
between Glu-112 and Lys-336 (12). In the A-chain of the dimer,
this distance is 3.9 Å, and in the B-chain, it is 2.6 Å. The positive
cooperativity was impaired somewhat in the single AspAla
mutants (Table 1). Therefore, the maximal activation of the AC
by cAMP routinely exceeded 400-fold in all full-length GAF
constructs (Table 1). The removal of the inserts invariably
resulted in the absence of positive cooperativity (Table 1), as also
observed for the cyaB1 AC and the chimeras containing PDE2
and PDE5 GAF domains and the cyaB1 AC (ref. 9 and unpub-
lished data). Furthermore, the stimulation factor in all shGAF
constructs dropped dramatically (Table 1). It appeared that each
cyaB2 GAF domain was still capable of individually activating
AC activity, albeit with different affinities and potencies. Only
when both aspartates were mutated to Ala in cyaB2 shGAF was
most activation lost; moreover, the small remaining activation
did not show positive cooperativity.
Considering the similarity at the amino acid level within
individual GAF domains of mammalian PDEs and cyanobacte-
rial ACs, it is highly likely that the tandem domains evolved by
gene duplication. Probably, a single, functional GAF domain was
duplicated, resulting in a tandem GAF ensemble with two
equally functional GAF domains. This, in turn, likely allowed
positive cooperativity to be expressed, thereby making such a
signaling unit immensely responsive to subtle changes in ligand
concentration (e.g., see Fig. 2A). Over time, such tandem GAF
domains presumably further evolved by mutation, with the result
that in some cases only one of the two domains signals, as is the
case in the tandem GAF domains of mammalian PDE2 and
probably PDE5 (10, 11, 17). This leaves the possibility for the
second GAF domain to acquire a new function, e.g., in dimer-
ization or binding to another molecule. Therefore, along the way
of such an evolutionary process, we may expect several func-
tional intermediates. It would appear that the tandem cyaB2
GAF domains are such an early evolutionary intermediate where
both GAF domains still participate in allosteric activation by
cAMP.
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